SML2856

Degarelix acetate

≥98% (HPLC), powder, GnRH receptor antagonist

• Synonym(e): ASP3550 acetate, Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-hydroorotyl)-D4Aph(carbamoyl)-Leu-ILys-Pro-DAla-NH2 acetate salt, FE 200486, FE200486, N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide acetate salt
• Empirische Formel (Hill-System): C₈₂H₁₀₃ClN₁₈O₁₆ · xC₂H₄O₂
• CAS-Nummer: 934016-19-0
• Molekulargewicht: 1632.26 (free base basis)
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Produktbezeichnung: Degarelix acetate, ≥98% (HPLC)
• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Lagertemp.: −20°C
• SMILES String: Clc1ccc(cc1)C[C@@H](NC(=O)[C@H](NC(=O)C)Cc7cc8c(cc7)cccc8)C(=O)N[C@H](Cc6cnccc6)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc4ccc(cc4)NC(=O)[C@H]5NC(=O)NC(=O)C5)C(=O)N[C@H](Cc3ccc(cc3)NC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2[C@@H](CCC2)C(=O)N[C@H](C)
• InChI: 1S/C82H103ClN18O16.C2H4O2/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52;1-2(3)4/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117);1H3,(H,3,4)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+;/m1./s1
• InChIKey: AUTFSFUMNFDPLH-KYMMNHPFSA-N

Beschreibung

Biochem./physiol. Wirkung

Degarelix acetate (FE200486) is a gonadotropin-/luteinizing hormone-/follicle-stimulating hormone-releasing hormone (GnRH, LHRH, FSH-RH) receptor antagonist that inhibits plasma testosterone for more than 40 days following a single s.c. dosage of 2 mg/kg in rats and monkeys, showing longer in vivo duration than abarelix, ganirelix, cetrorelix, azaline B or D-Trp6-LHRH, and exhibiting only weak histamine-releasing potency in isolated rat mast cells. Bi-weekly s.c. dosing (2 mg/kg) is efficacious in suppressing the growth of human prostate cancer PAC120 xenograft-derived tumors in mice in vivo.

Gonadotropin-releasing hormone (GnRH, LHRH, FSH-RH) receptor antagonist with in vivo efficacy against hormone-dependent prostate cancer growth.

Sicherheitshinweise

• Piktogramme: GHS08
• Signalwort: Danger
• H-Sätze: H360FD
• P-Sätze: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Gefahreneinstufungen: Repr. 1B
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable